文献速递免疫规划传染病防控与疫情报告

婴儿期卡介苗接种与全生命周期肺结核及肺外结核风险:系统综述与个体参与者数据Meta分析

Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis.
PubMed 文献 · Lancet Glob Health · 2022-01-01

该系统综述与个体参与者数据Meta分析纳入17个国家26项队列研究共68552名结核接触者,发现婴儿期卡介苗接种对全年龄组所有结核总体有效性为18%(aOR 0.82,95%CI 0.74-0.91),仅对5岁以下儿童有显著保护(aOR 0.63,95%CI 0.49-0.81),对青少年和成人无效。

要点

  • 婴儿期卡介苗接种对5岁以下儿童所有结核有显著保护(aOR 0.63,95%CI 0.49-0.81)。
  • 卡介苗对肺结核有显著保护(aOR 0.81,95%CI 0.70-0.94),对肺外结核无显著保护(aOR 0.96,95%CI 0.65-1.41)。
  • 在结核菌素皮肤试验或IFNγ释放试验阳性的接触者中,卡介苗对5岁以下(aOR 0.68)和5-9岁(aOR 0.62)均有显著保护。

核心结论

  • 婴儿期卡介苗接种可有效预防幼儿结核病,但对青少年和成人无效,因此需要在较大人群中加强免疫保护。

研究设计与样本

  • 系统综述与个体参与者数据Meta分析,检索MEDLINE、Web of Science、BIOSIS和Embase(1998年1月1日至2018年4月7日,无语言限制),纳入17个国家26项结核接触者队列研究,共68552名参与者。

主要发现

  • 68552名参与者中1782名(2.6%)发生结核:卡介苗接种组49686人中1309人(2.6%),未接种组18866人中473人(2.5%)。
  • 卡介苗对全年龄组所有结核总体有效性为18%(aOR 0.82,95%CI 0.74-0.91),仅对5岁以下儿童有显著保护(aOR 0.63,95%CI 0.49-0.81)。
  • 在结核菌素皮肤试验或IFNγ释放试验阳性的接触者中,卡介苗对全部参与者有显著保护(aOR 0.81,95%CI 0.69-0.96),5岁以下aOR 0.68(95%CI 0.47-0.97),5-9岁aOR 0.62(95%CI 0.38-0.99)。
  • 在试验阴性的接触者中无保护效应,除非年龄小于5岁(aOR 0.54,95%CI 0.32-0.90)。
  • 14项队列报告了肺结核与肺外结核(n=57421):卡介苗对肺结核有显著保护(接种组41119人中916人[2.2%] vs 未接种组16161人中334人[2.1%];aOR 0.81,95%CI 0.70-0.94),对肺外结核无显著保护(接种组40318人中106人[0.3%] vs 未接种组15865人中38人[0.2%];aOR 0.96,95%CI 0.65-1.41)。

临床怎么用

  • 作者认为,婴儿期卡介苗接种可有效预防幼儿结核病,但对青少年和成人无效,因此需要在较大人群中加强免疫保护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BCG vaccines are given to more than 100 million children every year, but there is considerable debate regarding the effectiveness of BCG vaccination in preventing tuberculosis and death, particularly among older children and adults. We therefore aimed to investigate the age-specific impact of infant BCG vaccination on tuberculosis (pulmonary and extrapulmonary) development and mortality. METHODS: In this systematic review and individual participant data meta-analysis, we searched MEDLINE, Web of Science, BIOSIS, and Embase without language restrictions for case-contact cohort studies of tuberculosis contacts published between Jan 1, 1998, and April 7, 2018. Search terms included "mycobacterium tuberculosis", "TB", "tuberculosis", and "contact". We excluded cohort studies that did not provide information on BCG vaccination or were done in countries that did not recommend BCG vaccination at birth. Individual-level participant data for a prespecified list of variables, including the characteristics of the exposed participant (contact), the index case, and the environment, were requested from authors of all eligible studies. Our primary outcome was a composite of prevalent (diagnosed at or within 90 days of baseline) and incident (diagnosed more than 90 days after baseline) tuberculosis in contacts exposed to tuberculosis. Secondary outcomes were pulmonary tuberculosis, extrapulmonary tuberculosis, and mortality. We derived adjusted odds ratios (aORs) using mixed-effects, binary, multivariable logistic regression analyses with study-level random effects, adjusting for the variable of interest, baseline age, sex, previous tuberculosis, and whether data were collected prospectively or retrospectively. We stratified our results by contact age and Mycobacterium tuberculosis infection status. This study is registered with PROSPERO, CRD42020180512. FINDINGS: We identified 14 927 original records from our database searches. We included participant-level data from 26 cohort studies done in 17 countries in our meta-analysis. Among 68 552 participants, 1782 (2·6%) developed tuberculosis (1309 [2·6%] of 49 686 BCG-vaccinated participants vs 473 [2·5%] of 18 866 unvaccinated participants). The overall effectiveness of BCG vaccination against all tuberculosis was 18% (aOR 0·82, 95% CI 0·74-0·91). When stratified by age, BCG vaccination only significantly protected against all tuberculosis in children younger than 5 years (aOR 0·63, 95% CI 0·49-0·81). Among contacts with a positive tuberculin skin test or IFNγ release assay, BCG vaccination significantly protected against tuberculosis among all participants (aOR 0·81, 95% CI 0·69-0·96), participants younger than 5 years (0·68, 0·47-0·97), and participants aged 5-9 years (0·62, 0·38-0·99). There was no protective effect among those with negative tests, unless they were younger than 5 years (0·54, 0·32-0·90). 14 cohorts reported on whether tuberculosis was pulmonary or extrapulmonary (n=57 421). BCG vaccination significantly protected against pulmonary tuberculosis among all participants (916 [2·2%] in 41 119 vaccinated participants vs 334 [2·1%] in 16 161 unvaccinated participants; aOR 0·81, 0·70-0·94) but not against extrapulmonary tuberculosis (106 [0·3%] in 40 318 vaccinated participants vs 38 [0·2%] in 15 865 unvaccinated participants; 0·96, 0·65-1·41). In the four studies with mortality data, BCG vaccination was significantly protective against death (0·25, 0·13-0·49). INTERPRETATION: Our results suggest that BCG vaccination at birth is effective at preventing tuberculosis in young children but is ineffective in adolescents and adults. Immunoprotection therefore needs to be boosted in older populations. FUNDING: National Institutes of Health.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Martinez L, Cords O, Liu Q, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health. 2022. PMID: 35961354. doi:10.1016/S2214-109X(22)00283-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。